We are proudly launching a new 47-plex drug target assay today! Based on proprietary Hyperplex™ technology the panel quantifies 47 drug targets of FDA-approved drugs (see below). Hyperplex™ is the most comprehensive pathway analysis platform in the market (>1,250 biomarkers, >400 phosphoproteins).
Talk to a scientist today: hello@assay-engineers.com
Drugs in the panel: Abemaciclib Afatinib Axitinib Azacitidine Bevacizumab Bosutinib Brigatinib Cabozantinib Cetuximab Cobimetinib Copanlisib Crizotinib Dabrafenib Dasatinib Docetaxel Eribulin Erlotinib Everolimus Gefitinib Idelalisib Imatinib Lapatinib Lenvatinib Midostaurin Necitumumab Neratinib Nilotinib Olaratumab Osimertinib Paclitaxel Palbociclib Panitumumab Pazopanib Pertuzumab Ponatinib Ramucirumab Regorafenib Ribociclib Ruxolitinib Sunitinib Temsirolimus Trametinib Trastuzumab Vandetanib Vemurafenib Venetoclax Ziv-Aflibercept
